Moleculin Biotech Inc

NASDAQ:MBRX   3:25:46 PM EDT
3.59
-0.09 (-2.45%)
Products, Regulatory, Other Pre-Announcement

Moleculin Biotech Inc - Commences Phase 1B/2 Clinical Trial Of Annamycin For Treatment Of Sarcoma Lung Metastases

Published: 05/25/2021 13:40 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Biotech Inc - Commences Phase 1b/2 Clinical Trial of Annamycin for Treatment of Sarcoma Lung Metastases.
Moleculin Biotech Inc - Patient Enrollment for Phase 1b/2 Clinical Trial on Track to Begin in Current Quarter.
Moleculin Biotech Inc - Interim Data From Phase 1b/2 Clinical Trial Expected in Second Half of 2022.
Moleculin Biotech Inc - Also Expects Second Phase 1b/2 Clinical Trial of Annamycin in Sarcoma Lung Metastases to Be Initiated in 2021.